Article

Laser photocoagulation associated with consistent visual acuity

Laser photocoagulation seems to be associated with stable rates of visual acuity up to 2 years after treatment for diabetic retinopathy.

Key Points

"A substantial percentage of patients with diabetes have diabetic retinopathy, and between 11% and 17% have sight-threatening retinopathy," he said. "We aimed to determine the visual outcomes, the changes in VA over time, and to identify the characteristics of patients with poor visual outcomes following laser photocoagulation for diabetic retinopathy."

Dr. Tham and colleagues conducted a retrospective analysis of 503 consecutive eyes of 356 patients who underwent laser photocoagulation during a 1-year period and followed those patients for 2 years after treatment.

"Overall, 7% of patients had VA worse than 20/200 1 year after laser treatment, while at the 2-year follow-up, 4.3% of patients had VA worse than 20/200," Dr. Tham said. "For all subgroups of patients, there was a decrease in the percentage of patients with VA of 20/200 or worse 2 years after treatment. However, there was a higher percentage of patients with poor VA in the group with combined pathologies (14% and 9% at 1 and 2 years, respectively). About 8% of patients lost more than three lines of Snellen acuity at 1 and 2 years after treatment, but the percentage was higher (10.3%) among those with combined pathologies."

Evaluations at three points

The investigators evaluated the changes in the VA at baseline and at 1 and 2 years after treatment. Dr. Tham provided some examples of the findings.

In the range of 20/20 to 20/40, 84% of patients were in that range at 1 year, and about 15% had a decrease in VA to 20/40 to 20/150. For the patients in the worst VA range of 20/200 or worse, 58% of patients still were in that range at 1 year, whereas 42% had an improvement in VA.

"Generally, the majority of patients tend to remain in the same VA range over the course of the study. That was also true for the patients with clinically significant macular edema," he said. "However, for those with combined pathologies who had a baseline VA of 20/40 to 20/150, only 45% remained within that range, and 38% had improvements in VA at 1 year.

"For those with combined pathologies, less than half of the patients with retinopathy had stable vision 1 and 2 years after treatment; about half had improved VA at the 1-and 2-year time points," Dr. Tham continued. "Of those in the lowest VA range, 83% had improvement in VA into the middle range at the 1-year examination, and 17% improved to the highest range at 1 year."

Primary risk factor

The primary risk factor for poor visual outcomes is a low VA level, i.e., 20/200, at baseline. The finding was similar to that of previously reported studies.

"The most important finding of this study is that we are now able to counsel patients with actual data with regards to visual outcomes post-laser photocoagulation," Dr. Tham concluded. "As patients are generally concerned with their visual outcomes after laser treatment, based on this study we can now tell them with confidence that, in general, the VA at baseline will remain the same after laser treatment. In fact, their VA may even improve for certain conditions."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.